Yarrow Bioscience director reports option holdings

Yarrow Bioscience, Inc., formerly VYNE Therapeutics Inc., reports that director Steven L. Hoerter holds a stock option to buy 87,820 shares of Issuer Common Stock at an exercise price of $6.19 per share, expiring on April 17, 2036.

Rhea-AI Filing Summary

Yarrow Bioscience, Inc., formerly VYNE Therapeutics Inc., reports that director Steven L. Hoerter holds a stock option to buy 87,820 shares of Issuer Common Stock at an exercise price of $6.19 per share, expiring on April 17, 2036.

The option was assumed in a merger effective July 27, 2026, converting prior Yarrow options into options on Issuer Common Stock on the same terms. One quarter of this option vests on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to Hoerter’s continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hoerter Steven L.

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) F1, F2, F3	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 87,820 contracts (Direct)

Footnotes (3)

1. F1. Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").
2. F2. Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.
3. F3. This option represents a right to purchase 87,820 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

Underlying option shares: 87,820 shares Exercise price: $6.19 per share Par value: $0.0001 per share +3 more

6 metrics

Underlying option shares 87,820 shares Shares of Issuer Common Stock underlying Steven L. Hoerter’s stock option holding

Exercise price $6.19 per share Exercise price of the Stock Option (Right to Buy) on Issuer Common Stock

Par value $0.0001 per share Par value of the Issuer Common Stock underlying the reported stock option

Merger Effective Time July 27, 2026 Date when a VYNE subsidiary merged with and into Yarrow Bioscience, Inc.

Option expiration April 17, 2036 Expiration date of the stock option assumed in the merger

Initial vesting date April 17, 2027 One quarter of the 87,820-share option vests on this date

Key Terms

Effective Time, Merger, Issuer Common Stock, Stock Option (Right to Buy

4 terms

Effective Time regulatory

"Effective as of July 27, 2026 (the Effective Time), a subsidiary merged with Yarrow"

The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.

Merger regulatory

"A wholly owned subsidiary of VYNE Therapeutics Inc. merged with and into Yarrow"

A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.

Issuer Common Stock financial

"Represents options to purchase shares of common stock of the Issuer (Issuer Common Stock)"

Stock Option (Right to Buy financial

"Stock Option (Right to Buy) reported as a derivative holding by the director"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock option holding does VYNE/Yarrow director Steven L. Hoerter report?

Steven L. Hoerter reports holding a stock option for 87,820 shares of Yarrow Bioscience Issuer Common Stock at an exercise price of $6.19 per share. The option expires on April 17, 2036 and was assumed in connection with the Yarrow–VYNE merger.

How did the Yarrow–VYNE merger affect director equity reported for VYNE?

At the merger’s Effective Time on July 27, 2026, a VYNE subsidiary merged into Yarrow, which became a wholly owned subsidiary. VYNE then changed its name to Yarrow Bioscience, Inc., and existing Yarrow options held by Hoerter were converted into options on Issuer Common Stock.

What is the vesting schedule for Steven L. Hoerter’s 87,820-share option at VYNE (Yarrow)?

The option to purchase 87,820 shares vests over four years: one quarter vests on April 17, 2027. The remaining three quarters vest in equal monthly installments over the next three years, contingent on Hoerter’s continued service to Yarrow Bioscience, Inc.

What are the key terms of the Issuer Common Stock underlying VYNE’s reported option?

The option covers Issuer Common Stock with a par value of $0.0001 per share. It is a Stock Option (Right to Buy) with an exercise price of $6.19 per share, expiring on April 17, 2036, and reflects assumed pre-merger Yarrow options.

Does the Form 3 for VYNE/Yarrow show any recent insider purchases or sales?

No insider purchases or sales are reported; the filing lists a holding entry for a stock option. The Form 3 describes existing derivative ownership following the merger, rather than new buy or sell transactions, and shows 87,820 underlying shares held directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 09:11 PM Accepted by SEC EDGAR 07/29/2026 - 09:11 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hoerter Steven L.

(Last) (First) (Middle)

C/O YARROW BIOSCIENCE, INC.

470 JAMES STREET, SUITE 007

(Street)

NEW HAVEN CONNECTICUT 06513

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/27/2026

3. Issuer Name and Ticker or Trading Symbol
Yarrow Bioscience, Inc. [ YARW ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)(2)(3)	04/17/2036	Common Stock	87,820	$6.19	D

Explanation of Responses:

1. Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").

2. Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.

3. This option represents a right to purchase 87,820 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Tyler Zeronda, as attorney-in-fact for Steven L. Hoerter	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)